Botox in periodontics - Exploring new avenues

ABSTRACT

From a periodontal point of view, various factors contribute to facial aesthetics. In the recent past, studies have revealed that excessive gingival display is a factor that influences an individual’s smile line. Some literature exists to support that more than excessive gingival display of more than 3mm is considered unaesthetic and termed a ‘gummy smile’ (GS).

The prevalence of gummy smile has been 10% and to be more common in females. Gingival hyperplasia altered passive eruption, vertical maxillary excess, and upper-lip hypermobility can all result in excessive gingival display when a patient smile.

To select the correct treatment protocol, accurate diagnosis is essential. Various techniques have used to treat gummy smile which includes surgical and nonsurgical methods. Recently nonsurgical method using Botulinum toxin gained polarity considering that the method is minimally invasive.

Keywords
Botulinum toxin, gummy smile, bruxism, dental implants, masseteric Hypertrophy.

INTRODUCTION

Over the last decade, facial cosmetic procedures have become more common in dental and periodontal practices. As patient expectations are rising, the demand for facial aesthetics have prompted an evolution in techniques that optimize aesthetics. It is hypothesized that the first impression is the lasting impression and dental beauty is a vital constituent of the impression.

As various emotions can be expressed through a smile, the need for a smile that glows are in demand. Dentofacial harmony relies on three important components teeth, lip, and gingival scaffold that governs the smile as it is a key factor for all expressions. Patient can encounter esthetic and psychological problems due to gummy smile (GS) as it leads lack of once own self confidence to smile.1

Periodontics is a branch of dentistry that not only deals with the tooth supporting structure but also with facial aesthetics and the harmony between the lips, teeth, and gingiva. From a periodontal point of view, various gingival factors contribute to facial aesthetics.2,3

Studies support that excessive gingival display have an influence on an individual's smile line.2 There is a rise in minimally invasive cosmetic procedures and the use of Botox type A (onabotulinumtoxinA) is one such procedure.4,5

Botulinum toxin is a lethal, naturally occurring neurotoxin produced by Clostridium botulinum.7 Presently seven serotypes of botulinum neurotoxin have been identified which include (serotypes A to G).8 Despite its lethal potential, the protein has other medical benefits.

Currently, there are three different forms of serotypes ie A botulinum toxin (Botox, Dysport, Xeomin) and only one form of type B botulinum toxin (MyoBloc) that have been commercialized for cosmetic and medical procedures.3

Botulinum toxin has been used within the medical and dental field for various purposes which include its application to facial esthetics,8 as an anti-wrinkle agents,10,11 and in the management of specific lacrimal gland disorders,12 chronic headaches,13 children with cerebral palsy,14 myo-functional pain and occlusal function,15 bruxism,16 dental implants,17 gummy smile.18

The aim of the current review is to discuss the use of botulinum toxin (BTX) as an alternative treatment modality in treating gummy smile and its application in the field of periodontics.
Botox and its applications in periodontics: BTX is used in the field of periodontics for the treatment of conditions, which include a gummy smile that defined as excessive gingival display of gingiva more than 2 mm, bruxism, immediate loading implants, sialorrhea, masseteric hypertrophy and parafunctional habit such as pathologic clenching.\(^{18-20}\) The etiology for GS was categorized into three factors which include bone gum and muscles.

Bone lead to excess vertical maxilla, the gum in delayed passive dental eruption, and the muscles in hyperfunctioning upper lip elevators.\(^2\)

**Factors affecting Botox injections**

1. Dosage - Differs among females and males governed by lip muscle volume.\(^{23-25}\) (Table 1)
2. Precise injection of intramuscular BTX at Yonsei point.\(^26\) (Figure 1)

**Diagnosis of gummy smile (GM)**

Correct diagnosis of GM is done by identifying the etiology with the help of medical and dental history that provides patient age and eruption stage of dentition along with contributing factors for GM. Followed by periodontal examination to measure width of attached gingiva, probing pocket depth and clinical attachment loss to rule out any pathologic and nonpathological changes in the architecture of the periodontium.

Later analysis of face done to evaluate vertical maxillary excess (VME) by cephalometric analysis. Lip analysis done both in static and dynamic posture to assess lip length, hypermobility, or both. Dentoalveolar analysis is done to measure the interlabial gap by analyzing 3D position of the incisors during rest position. 0-4 mm is considered normal interlabial gap.\(^{21,22}\)

**Mechanism of Action**

BTX inhibits neuromuscular transmission by blocking the extracellular release of acetylcholine thereby inhibiting signals to muscle cells which in turn leads to reduced muscle action or overall lack of muscle contraction as shown below.\(^{19}\)

**Side effects of Botox injections**

Though Botox use is minimally invasive, it still leads to certain side effects. They can be categorized as common side effects, improper injection technique and drug over dosage.\(^{25}\) Common side effects comprise pain, infection, inflammation, bruising and hematoma formation, loss of muscle strength and, muscle weakness as well as less commonly, nerve palsy.\(^{27}\)

Improper injection technique could affect the smile symmetry and effect function manifesting as, difficulty in talking, mastication and/or drinking. Drug overdose might lead to a ‘loose lip’, dropping to beneath the level of the marginal gingiva, affecting teeth visibility during smiling.\(^{28}\)

**Uses of Botox in periodontics**

**Treatment of gummy smile**

‘Gummy smile’ is a term that refers to excessive maxillary gingival display more than 2 mm during smiling. Its prevalence has been reported as 10% and most common in females aged 20-30 years.\(^{29,30}\) Etiology for GM vary from short or hyperactive upper lip muscles such as levator labii superioris (LLS), levator labii superioris alaeque nasii (LLAN), levator anguli oris (LAO), depressor septi (DP) and the zygomatic major (ZM) zygomatic minor (Zmi), or other factors such as altered passive eruption of teeth, dentoalveolar extrusion, vertical maxillary excess. Appropriate diagnosis will lead to effective treatment.

GS is diagnosed as low, moderate, and high based amount of gingiva exposed while smiling using Goldstein classification.\(^{25}\) Various techniques have used to treat gummy smile which includes surgical and non-surgical methods. Recently nonsurgical method using Botulinum toxin gained polarity considering that the method is minimally invasive. BTX is mainly used in patients with hyperactive upper
lip elevator muscles which leads to flaccid paralysis of upper lip thus resulting in the mild gingival display. Site of Injection is considered as Yonsei site, which is a core of the triangle constituting LLS, Zmi, LLSAN. Injection of BTX at this point results in muscle paralysis, that intern decrease upper lip lift due to decline in muscles contractability leading to less gingival display while smiling. The temporalis and masseter muscles are muscles that may be affected in an individual with a bruxism habit. BTX can be used as a virtuous alternative treatment option for bruxism as it reduces the muscle contraction by its inhibitory action on acetylcholine release. It also relaxes temporalis and masseter muscle which provide all the power for bruxism. It has an edge over other treatment options such as oral splint, behavioral approaches, and muscle relaxants in sleep bruxism cases when compared to conservative approach. As its non in vase conservator approach as it reduces tooth wear and protects early implant loss.

In Dental Implantology

There may be therapeutic benefit of BTX administration to the muscles of mastication in patients with dental implants as it may aid favorable osseointegration during the initial phase of healing. Implant failures occur due bruxism or due to excessive functional force. Odds ratio of implant failure has been shown to be 2.71 in bruxism patients vs. non-bruxers. Excessive functional force leads micro-fractures at the bone-implant interface as it exceeds the bone physiologic threshold. This can be prevented by injection of BTX type A to masticatory muscles. This leads to relaxation of masticatory muscles as well as relief the abnormal forces which results in better implant osseointegration as BTX weakens the muscle for a period of three to four months.

Treatment of Bruxism

The temporalis and masseter muscles are muscles that may be affected in an individual with a bruxism habit. BTX can be used as a virtuous alternative treatment option for bruxism as it reduces the muscle contraction by its inhibitory action on acetylcholine release. It also relaxes temporalis and masseter muscle which provide all the power for bruxism. It has an edge over other treatment options such as oral splint, behavioral approaches, and muscle relaxants in sleep bruxism cases when compared to conservative approach. As its non in vase conservator approach as it reduces tooth wear and protects early implant loss.

Contraindications

1. Impractical patients.
3. Individual hypersensitive to BTX-A or BTX-B.
4. Patients under medication such as aminoglycosides, penicillamine, quinine, and calcium blockers that hamper conduction of neuromuscular impulses.
5. Women who are pregnant or lactating.

CONCLUSION

Botox can be used as an adjunct non-invasive, atraumatic technique to treat patients with a gummy smile, bruxism, drooling saliva, masseteric hypertrophy, pathological clenching and after immediate implant placement. It is quite a simple procedure that offers an excellent alternative to other procedures with higher morbidity rates. It can meet the expectations of the patient and solve aesthetic problems without surgical intervention. However, every technique has its own added advantages and disadvantages so do with Botox. A word of caution is necessary with its applications as its effects last from weeks to months.

Treatment of Sialorrhea

Excessive salivation is termed Sialorrhea. Though various treatment methods are available, of late the use of BTX has gained attention. By injecting BTX into the parotid and submaxillary salivary glands, stimulation of the cholinergic receptors is impeded and thus reducing salivary flow. This technique is simple enough to use in patients with special needs with excessive salivation.

Treatment of Masseteric Hypertrophy

Masseteric hypertrophy usually presents as bilateral soft swelling adjacent to the angle of the mandible, coupled with facial pain. This hypertrophy may manifest as facial disfigurement. Various treatment methods are available interventional technique such as BTX injections has been applied to this condition, with caution.

Figure 2. Muscles involved in facial smile and site of injection of BTX.
<table>
<thead>
<tr>
<th>S.No</th>
<th>Authors</th>
<th>Study Type</th>
<th>Condition</th>
<th>Type and dose of Botox</th>
<th>Muscles involved</th>
<th>Adverse effect reported</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Polo M 2005</td>
<td>Case Report</td>
<td>GS</td>
<td>BTX-A - 0.25 U per muscle bilaterally</td>
<td>LLS, LLSAN, and at the overlap areas of the LLS and Zmi muscles.</td>
<td>Not reported</td>
<td>Authors reported that treatment modality was effective, producing esthetically acceptable smiles.</td>
</tr>
<tr>
<td>2</td>
<td>Polo M 2008</td>
<td>Prospective</td>
<td>GS</td>
<td>BTA - A - 2.5 U/0.1 mL</td>
<td>Yonsei point - LLSAN and LLS and the LLS and Zmi</td>
<td>Pain, twitching and headache</td>
<td>Mean gingival display had declined from 5.2 mm (+/-1.4 mm) to 0.09 mm (+/-1.06 mm) in 2 weeks. 24 weeks, average gingival display was 2.9mm.</td>
</tr>
<tr>
<td>3</td>
<td>Mazzuco R 2010</td>
<td>Prospective</td>
<td>GS</td>
<td>BTA - A - 2.5 U/0.1 mL</td>
<td>LLSAN and LLS and the LLS and Zmi</td>
<td>Asymmetrical smile</td>
<td>Authors reported general average improvement of 75.09%.</td>
</tr>
<tr>
<td>4</td>
<td>Sucupira E 2012</td>
<td>Prospective</td>
<td>GS</td>
<td>BTA - A - 3.1 U/0.1 mL</td>
<td>LLSAN</td>
<td>Not reported</td>
<td>Authors reported average satisfaction level of 9.75 on a 10-point scale.</td>
</tr>
<tr>
<td>5</td>
<td>Somaiah S 2013</td>
<td>Prospective</td>
<td>GS</td>
<td>2.5 U R</td>
<td>LLSAN, LLS, Zmi</td>
<td>Not reported</td>
<td>Authors reported decrease in the gingival display (mean 75.09%). Mean gingival display decreased from 4.7 ± 1.06 from the 1st week to 0.95 ± 0.72 in the second week. After 12 weeks it was 3.7 ± 1.16mm</td>
</tr>
<tr>
<td>6</td>
<td>Suber JS 2014</td>
<td>Prospective</td>
<td>GS</td>
<td>BTA - A - 2 U/0.1 mL</td>
<td>LLSAN, LLS</td>
<td>Not reported</td>
<td>Authors reported 85% and 83% reduction in gingival display for both central incisor and canines. Central incisor displayed average reduction in GS from 4.89 mm to 0.75 mm and canines from 4.25 mm to 0.74 mm.</td>
</tr>
<tr>
<td>7</td>
<td>Al-Fouzan AF 2017</td>
<td>In vivo study</td>
<td>GS</td>
<td>Botox type I</td>
<td>LLS, LLSAN</td>
<td>Not reported</td>
<td>Authors reported clear reduction in gingival display after 2 weeks with 96.6% reduction in GS.</td>
</tr>
<tr>
<td>8</td>
<td>Pedron IG 2018</td>
<td>Case Report</td>
<td>GS</td>
<td>2 U/1.7ml</td>
<td>Laterally to each nostril</td>
<td>Not reported</td>
<td>Authors reported reduction in GS.</td>
</tr>
<tr>
<td>9</td>
<td>Araujo JP 2018</td>
<td>Case report</td>
<td>GS</td>
<td>BTX A - 2 IU 5 IU</td>
<td>LLS minor zygomaticus bilaterally</td>
<td>Not reported</td>
<td>Authors observed a significant decrease of gingival exposure (4mm) after the period of four injection sessions in an overall interval of 20 months.</td>
</tr>
<tr>
<td>10</td>
<td>Mostafa D 2018</td>
<td>Case report</td>
<td>GS</td>
<td>BTX A</td>
<td>4 units were injected on each side of the nasolabial fold, 1 cm lateral and below the nasal ala - Yonsei point</td>
<td>Difficulty in contracting her lips during kissing</td>
<td>Authors observed results that was extremely significant, as the exposed gingival area became 1 mm. However, after 11 weeks, the gingival exposed distance started to increase 1-1.5 mm returning back to its post-surgical appearance after 6 months.</td>
</tr>
<tr>
<td>11</td>
<td>Duruel O 2019</td>
<td>Prospective</td>
<td>GS</td>
<td>BTX A</td>
<td>Yonsei point - LLSAN and LLS and the LLS and Zmi</td>
<td>No complications reported</td>
<td>Authors reported gingival display for each tooth between second premolars was measured less than 3 mm, and the percentage of improvement for each case was calculated 100%.</td>
</tr>
<tr>
<td>12</td>
<td>Al Wayli H - 2019</td>
<td>Prospective</td>
<td>GS</td>
<td>(BTX-A)</td>
<td>Yonsei point</td>
<td>Not reported</td>
<td>Authors reported that single dose of BTX-A injected at the Yonsei point was effective in the treatment of GS and achieved better results than multiple injections at various sites.</td>
</tr>
</tbody>
</table>
References

25. Botulinum Toxin in Dentistry, Diana Mostafa, Additional information is available at the end of the chapter. http://dx.doi.org/10.5772/intechopen.78950. Provisional chapter. DOI: 10.5772/intechopen.78950. © 2016 The Author(s). Licensee Intech. This chapter is distributed under the terms of the Creative Commons. Additional information is available at the end of.

NOTICE of the 21st ANNUAL GENERAL MEETING (AGM) of The South African Dental Association NPC (SADA)

Notice is hereby given that the 21st Annual General Meeting of Members (AGM) of The South African Dental Association (SADA) NPC, will be held on Thursday, 3 June 2021 at 18h00, which will be conducted virtually and electronically on this date through the Zoom virtual meeting platform or similar digital platform. The Agenda with any supporting documents for the meeting will be posted on the SADA website.

SADA is your Association and your voice counts.

KC Makhubele
Chief Executive Officer
March 2021